Drug Profile

CHS 3318

Alternative Names: CHS-3318

Latest Information Update: 12 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Coherus BioSciences
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; CCR8 receptor antagonists; Regulatory T-lymphocyte inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

31 Oct 2022 Discontinued - Preclinical for Solid tumours in USA (Parenteral)
01 Apr 2022 Coherus expects to file investigational new drug (IND) applications to the US FDA for CHS 3318 in Solid tumors, in 2024
30 Mar 2022 Preclinical trials in Solid tumours in USA (Parenteral), prior to March 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com